Current Report Filing (8-k)
June 19 2017 - 11:38AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): June 16, 2017
BOSTON
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
000-54586
|
27-0801073
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification Number)
|
354
Merrimack Street #4
,
Lawrence
,
MA
01843
(Address
of principal executive offices) (zip code)
(603)
935-9799
(Registrant's
telephone number, including area code)
Copies
to:
Stephen
M. Fleming
Fleming
PLLC
49
Front Street, Suite 206
Rockville
Centre, New York 11570
Phone:
(516) 833-5034
Fax:
(516) 977-1209
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory
Agreements of Certain Officers
On
June 16, 2017, Rom Eliaz resigned as a director of Boston Therapeutics, Inc.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
BOSTON THERAPEUTICS, INC.
|
|
|
|
Date: June 19, 2017
|
|
By:
/s/
Carl
Rausch
|
|
|
Name:
Carl
Rausch
|
|
|
Title: Chief Executive Officer
|